Marketing91

  • HOME
  • Marketing Concepts
    • Marketing
      • Retail Tutorials
    • Strategy
    • Management
    • Advertising
    • Branding
    • Market Research
    • Business
    • Finance
    • Sales
    • Career Guidance
    • Customer Management
    • TOP 10
  • Digital Concepts
    • Blogging
    • Search Engine Optimization
    • Social Media Marketing
    • Facebook Marketing
    • Internet Marketing
    • Ecommerce
  • Brands
    • Marketing Mix of Brands
    • SWOT analysis of Brands
    • Brands Strategy Analysis
    • Business Models
    • Brand Competitors
  • Videos
Home » SWOT articles » SWOT Analysis of Cipla

SWOT Analysis of Cipla

April 1, 2019 By Hitesh Bhasin Tagged With: SWOT articles

Cipla Limited manufactures and markets prescription drugs, active pharmaceutical ingredients (API) and veterinary products. Cipla generated an increase of 20 percent year-on-year in revenue in the FY 2016. The company is headquartered in Mumbai, India and has strong R&D and manufacturing facilities in India.

Table of Contents

  • Strengths in the SWOT Analysis of Cipla :
  • Weaknesses in the SWOT Analysis of Cipla :
  • Opportunities in the SWOT Analysis of Cipla :
  • Threat in the SWOT Analysis of Cipla :

Strengths in the SWOT Analysis of Cipla :

Strong R&D: Cipla has focused on developing new products as well as on improving drug delivery systems and expanding product applications. Cipla has set up strong Research and Development department for the same. The strong R&D facilities are well supported by many manufacturing plants across the cities.

SWOT Analysis of Cipla

The wide range of Products: Cipla has a broad product portfolio includes APIs and formulations for humans and animal healthcare products. Cipla has over 2000 products in over 65 categories and is constantly looking for expansion of its product portfolio.

Social and technological initiatives: Cipla provides and supports to cancer patients by providing them low-cost medicines and it also initiated a “No touch Breast Scan” which is a step forward to screening technology in India.

Well recognised by various regulatory authorities: Cipla’s products are well recognised by regulatory authorities of India, USA, Germany and the UK etc. this provides credibility to the products of Cipla.

SWOT Analysis of Cipla

Weaknesses in the SWOT Analysis of Cipla :

Lack of significant presence in developed countries: India is Cipla’s major market for revenue generation. Although, Cipla has the presence in over 100 other countries but it has low significance in other developed markets and hence is highly dependent on the Indian market.

Negative campaigning: AIDS healthcare foundation had challenged Cipla over pricing of its drug for AIDS, which keep the drugs out of reach of many in need. This brought a negative publicity for Cipla.

Limited market share: High competition from local as well as multinational pharmaceutical companies limits market share for Cipla and doesn’t allow rapid growth.

Opportunities in the SWOT Analysis of Cipla :

Strategic Expansion: In the recent past, Cipla has been expanding its business through initiatives such as investments, partnerships and acquisitions in India as well as in the international market. For instance, Cipla invested in a biotech manufacturing facility in South Africa. It also acquired InvaGen pharmaceuticals in the USA etc.

Treatment of HIV: Cipla offers a wide range of ARV products through C-GA for the treatment of HIV/AIDS in both children and adults. The growing number of patients can be provided cure by Cipla’s medicines.

Grow in Emerging markets: Cipla should look forward to growing in emerging markets, especially places where medical infrastructure is improving and hence pharmaceutical is also expected to grow.

Threat in the SWOT Analysis of Cipla :

Drug Pricing control methods in India: Governments have influence over pricing of a drug through national health organisations. In India, a new pricing policy under Drug price control has been proposed which can have a negative impact on the industry. Changes in pricing policy affect pharmaceutical companies.

Intense competition in generics industry: There is intense competition in the Indian generics industry from major competitors such as Lupin, Sun Pharma etc.  This affects growth potential as well as limits the market share for Cipla.

Fluctuation in Exchange rates: Any changes in the exchange rates affect the company’s financial agreement with other countries and thus can affect profitability.

Related posts:

  1. SWOT ANALYSIS OF UBER – UBER SWOT analysis
  2. SWOT Analysis of Bajaj Auto
  3. SWOT Analysis of Chanel
  4. SWOT Analysis of Havells India – Havells India SWOT Analysis
  5. SWOT Analysis of Pepsi – PepsiCo SWOT analysis
  6. SWOT Analysis of Airbnb
  7. SWOT Analysis of ARMANI
  8. SWOT Analysis of ASUS
  9. SWOT Analysis of Bacardi
  10. SWOT analysis of Patanjali – Patanjali SWOT analysis
GET DAILY MARKETING UPDATES

About Hitesh Bhasin

I love writing about the latest in marketing & advertising. I am a serial entrepreneur & I created Marketing91 because I wanted my readers to stay ahead in this hectic business world.

Comments

  1. Madeleine says

    Thanks for sharing your thoughts about tinyurl.com.
    Regards

    Reply

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Advertisement
Recent Posts
  • 10 Leadership Behaviors Every Leader should Possess
  • 12 Essential Coaching Skills and How to Become a Good Coach
  • Compensatio Ratio or Compa-Ratio – Definition, Formula and Calculation
Advertisement

Marketing91

MORE INFO

  • About Marketing91
  • Privacy Policy
  • Cookie Policy
  • Disclaimer
  • Terms of Use
  • Advertise
  • Contact us
  • Sitemap
  • ISO 9001:2015 Certified

LEARN WITH US

  • Course on Market Segmentation
  • Course on Marketing Strategory Models

WE WRITE ON

  • Marketing
  • Small Business
  • Management
  • Internet Marketing
[email protected]

Copyright © 2020 Marketing91 All Rights Reserved